论文部分内容阅读
目的对阿莫西林舒巴坦,阿莫西林舒巴坦+阿奇霉素,头孢硫脒和头孢硫脒+阿奇霉素治疗儿童支气管肺炎进行药物经济学分析,为临床提供用药参考方案。方法采用回顾性分析4组治疗儿童支气管肺炎的方案的成本-效果。结果4组治疗儿童支气管肺炎的总有效率分别为91%以上,取得了较好的疗效,但药物治疗的成本-效果分析、增量成本-效果分析显示头孢硫脒优于其他3组药物。结论头孢硫脒治疗儿童支气管肺炎比阿莫西林舒巴坦,阿莫西林舒巴坦+阿奇霉素和头孢硫脒+阿奇霉素经济,符合药物经济学原则。
Objective To analyze the pharmacoeconomic analysis of amoxicillin and sulbactam, amoxicillin and sulbactam, azithromycin, cefathiamidine and cefathiamidine plus azithromycin in children with bronchopneumonia, and to provide reference for clinical use. Methods A retrospective analysis of four groups of children treated for bronchial pneumonia cost-effectiveness. Results The total effective rate of bronchopneumonia treated by children in the four groups was above 91% respectively, and the better curative effect was obtained. However, cost-effectiveness analysis and incremental cost-effectiveness analysis showed that cefathiamidine was superior to the other three groups of drugs. Conclusion Cefathiamidine treatment of children with bronchial pneumonia than amoxicillin and sulbactam, amoxicillin and sulbactam azithromycin and cefathiamidine azithromycin economy, in line with the principles of drug economics.